100 related articles for article (PubMed ID: 1812593)
21. Alteration of p16 and p15 genes in human uterine tumours.
Nakashima R; Fujita M; Enomoto T; Haba T; Yoshino K; Wada H; Kurachi H; Sasaki M; Wakasa K; Inoue M; Buzard G; Murata Y
Br J Cancer; 1999 May; 80(3-4):458-67. PubMed ID: 10408854
[TBL] [Abstract][Full Text] [Related]
22. Mutations of the Ki-ras oncogene in carcinoma of the endometrium.
Caduff RF; Johnston CM; Frank TS
Am J Pathol; 1995 Jan; 146(1):182-8. PubMed ID: 7856726
[TBL] [Abstract][Full Text] [Related]
23. Point mutations at codon 12 of C-K-ras in human endometrial carcinomas.
Lester DR; Cauchi MN
Cancer Lett; 1990 May; 51(1):7-10. PubMed ID: 2337900
[TBL] [Abstract][Full Text] [Related]
24. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Gynecol Oncol; 1996 Nov; 63(2):238-46. PubMed ID: 8910634
[TBL] [Abstract][Full Text] [Related]
25. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma.
Motojima K; Urano T; Nagata Y; Shiku H; Tsunoda T; Kanematsu T
Am J Gastroenterol; 1991 Dec; 86(12):1784-8. PubMed ID: 1962623
[TBL] [Abstract][Full Text] [Related]
26. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
27. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
28. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917
[TBL] [Abstract][Full Text] [Related]
29. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients.
Mariyama M; Kishi K; Nakamura K; Obata H; Nishimura S
Jpn J Cancer Res; 1989 Jul; 80(7):622-6. PubMed ID: 2507485
[TBL] [Abstract][Full Text] [Related]
30. Identification of H, K, and N-ras point mutations in stage IB cervical carcinoma.
Grendys EC; Barnes WA; Weitzel J; Sparkowski J; Schlegel R
Gynecol Oncol; 1997 May; 65(2):343-7. PubMed ID: 9159349
[TBL] [Abstract][Full Text] [Related]
31. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma.
Duggan BD; Felix JC; Muderspach LI; Tsao JL; Shibata DK
Cancer Res; 1994 Mar; 54(6):1604-7. PubMed ID: 8137266
[TBL] [Abstract][Full Text] [Related]
32. K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer.
Sagawa M; Saito Y; Fujimura S; Linnoila RI
Br J Cancer; 1998 Mar; 77(5):720-3. PubMed ID: 9514049
[TBL] [Abstract][Full Text] [Related]
33. [Detection of point mutation of Kirsten ras oncogene in pancreatic carcinoma by polymerase chain reaction].
Motojima K; Kohara N; Furui J; Terada M; Tsunoda T; Nagata Y; Urano K
Nihon Geka Gakkai Zasshi; 1991 Apr; 92(4):453-8. PubMed ID: 1870574
[TBL] [Abstract][Full Text] [Related]
34. [Detection of K-ras mutation from malignant cells in sputum with mutant-allele specific amplification (MASA) method].
Kimura S; Fukuchi K; Takeda S; Shin S; Saito D; Akamatsu S; Himeji Y; Chen GL; Watanabe H; Takagi Y
Rinsho Byori; 1995 Jul; 43(7):718-23. PubMed ID: 7674546
[TBL] [Abstract][Full Text] [Related]
35. Polymerase chain reaction/sequencing analysis of ras mutations in paraffin-embedded tissues as compared with 3T3 transfection and polymerase chain reaction/sequencing of frozen tumor deoxyribonucleic acids.
Goodrow TL; Prahalada SR; Storer RD; Manam SV; Leander KR; Kraynak AR; van Zwieten MJ; Nichols WW; Bradley MO
Lab Invest; 1992 Apr; 66(4):504-11. PubMed ID: 1583889
[TBL] [Abstract][Full Text] [Related]
36. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men.
Konishi N; Enomoto T; Buzard G; Ohshima M; Ward JM; Rice JM
Cancer; 1992 May; 69(9):2293-9. PubMed ID: 1562975
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium.
Mizuuchi H; Nasim S; Kudo R; Silverberg SG; Greenhouse S; Garrett CT
Cancer Res; 1992 May; 52(10):2777-81. PubMed ID: 1581890
[TBL] [Abstract][Full Text] [Related]
38. Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus.
Jiko K; Tsuda H; Sato S; Hirohashi S
Int J Cancer; 1994 Dec; 59(5):601-6. PubMed ID: 7960232
[TBL] [Abstract][Full Text] [Related]
39. Incidence of ras oncogene activation in lung carcinomas in Hong Kong.
Lung ML; Wong M; Lam WK; Lau KS; Kwan S; Fu KH; Cheung H; Yew WW
Cancer; 1992 Aug; 70(4):760-3. PubMed ID: 1322782
[TBL] [Abstract][Full Text] [Related]
40. Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma.
Sato S; Ito K; Ozawa N; Yajima A; Sasano H
Tohoku J Exp Med; 1991 Oct; 165(2):137-45. PubMed ID: 1687493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
